To this end, FAM118A has previously been identified as a potential gene target in glioma stem cells, in which a decrease in FAM118A expression, but increase in FAM118A protein levels, correlates with worse OS of patients with GBM (32). The gene discussed is SIRAL2; the disease is central nervous system cancer.